These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 21404138)

  • 1. Editorial: Thrombosis prophylaxis with new anticoagulants: Routine and specific risk groups.
    Kozek-Langenecker SA
    Wien Med Wochenschr; 2011 Feb; 161(3-4):53. PubMed ID: 21404138
    [No Abstract]   [Full Text] [Related]  

  • 2. Why is factor Xa not a better target than factor IIa for therapeutic inhibition of coagulation?
    Schulman S
    Semin Thromb Hemost; 2003 Dec; 29 Suppl 1():33-6. PubMed ID: 14730476
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Factor Xa inhibitors: today and beyond.
    Walenga JM; Jeske WP; Hoppensteadt D; Fareed J
    Curr Opin Investig Drugs; 2003 Mar; 4(3):272-81. PubMed ID: 12735228
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Is the monitoring of anti-Xa activity necessary in pregnant women undergoing thromboprophylaxis?
    O'Connell MP; O'Leary M; MacKeogh L; Murphy K; Keane DP
    Eur J Obstet Gynecol Reprod Biol; 2004 May; 114(1):12-4. PubMed ID: 15099863
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Factor Xa inhibitors: next-generation antithrombotic agents.
    Pinto DJ; Smallheer JM; Cheney DL; Knabb RM; Wexler RR
    J Med Chem; 2010 Sep; 53(17):6243-74. PubMed ID: 20503967
    [No Abstract]   [Full Text] [Related]  

  • 6. New anticoagulants for atrial fibrillation.
    De Caterina R; Kristensen SD; Renda G
    J Cardiovasc Med (Hagerstown); 2009 Jun; 10(6):446-53. PubMed ID: 19365276
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Thrombosis ABC, 5: No prophylaxis without bleeding risk. Safe navigation between Scylla and Charybdis].
    Stiefelhagen P
    MMW Fortschr Med; 1999 Oct; 141(43):42. PubMed ID: 10912121
    [No Abstract]   [Full Text] [Related]  

  • 8. An algal sulfated galactan has an unusual dual effect on venous thrombosis due to activation of factor XII and inhibition of the coagulation proteases.
    Melo FR; Mourão PA
    Thromb Haemost; 2008 Mar; 99(3):531-8. PubMed ID: 18327401
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Summary and perspectives. Rivaroxaban].
    Albaladejo P
    Ann Fr Anesth Reanim; 2008 Dec; 27 Suppl 3():S28-31. PubMed ID: 19185785
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Survival of heparins, oral anticoagulants, and aspirin after the year 2010.
    Fareed J; Hoppensteadt DA; Fareed D; Demir M; Wahi R; Clarke M; Adiguzel C; Bick R
    Semin Thromb Hemost; 2008 Feb; 34(1):58-73. PubMed ID: 18393143
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical management of thrombosis in inherited factor VII deficiency: a description of two cases.
    Arellano-Rodrigo E; Gironella M; Nicolau I; Vila M
    Thromb Haemost; 2009 Feb; 101(2):402-4. PubMed ID: 19190828
    [No Abstract]   [Full Text] [Related]  

  • 12. [Synthetic anticoagulation stands the test in internist patients, Thrombosis risk in immobilization cut in half].
    MMW Fortschr Med; 2003 Nov; 145(45):51. PubMed ID: 14712788
    [No Abstract]   [Full Text] [Related]  

  • 13. Adjunctive pharmacologic therapy in percutaneous coronary intervention: part II anticoagulant therapy.
    Kim SJ; Giugliano RP; Jang IK
    Coron Artery Dis; 2011 Mar; 22(1):113-21. PubMed ID: 21304293
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Limitations of the laboratory monitoring of heparin therapy. Scientific and Standardization Committee Communications: on behalf of the Control of Anticoagulation Subcommittee of the Scientific and Standardization Committee of the International Society of Thrombosis and Haemostasis.
    Greaves M;
    Thromb Haemost; 2002 Jan; 87(1):163-4. PubMed ID: 11848446
    [No Abstract]   [Full Text] [Related]  

  • 15. Factor Xa is a superior target to factor IIa for antithrombotic therapies.
    Büller HR
    Semin Thromb Hemost; 2003 Dec; 29 Suppl 1():37. PubMed ID: 14730477
    [No Abstract]   [Full Text] [Related]  

  • 16. Management of anticoagulation therapy for invasive procedures.
    Gaines KK
    Urol Nurs; 2005 Oct; 25(5):379-80. PubMed ID: 16294616
    [No Abstract]   [Full Text] [Related]  

  • 17. Recurrent miscarriages: caution regarding development of clinical trials using low molecular weight heparin and pregnancy.
    Misra D; Aledort L
    Am J Hematol; 2011 Feb; 86(2):235. PubMed ID: 21264918
    [No Abstract]   [Full Text] [Related]  

  • 18. Does a longer duration of oral factor Xa therapy increase the risk of bleeding or transaminitis?
    From AM; Hoganson DD; Erwin PJ
    Thromb Res; 2011 Mar; 127(3):202-9. PubMed ID: 21159363
    [TBL] [Abstract][Full Text] [Related]  

  • 19. DU-176b, an oral, direct Factor Xa antagonist.
    Hylek E
    Curr Opin Investig Drugs; 2007 Sep; 8(9):778-83. PubMed ID: 17729190
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Analysis of unfractionated heparin dose requirements to target therapeutic anti-Xa intensity during pregnancy.
    Clark NP; Delate T; Cleary SJ; Witt DM
    Thromb Res; 2010 May; 125(5):402-5. PubMed ID: 19699510
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.